Juno Therapeutics, Inc. (NASDAQ:JUNO) Quarterly Basic Net EPS At 2016-03-31

0

For the year ended 2016-03-31 Juno Therapeutics, Inc. (NASDAQ:JUNO) basic consolidated EPS came $-2.7157. Conversely, for the quarter ended 2016-03-31, it was $-2.7157.

EPS can be simply called as a fraction of profits that is disbursed against each outstanding share. It is measured using the formula – net profit/outstanding shares. The element ‘Per-share earnings’ is majorly utilized by market experts to give earnings and price projections. Suppose a group “S” announces a net profit of $15,000 in a given year. The count of outstanding shares is 300. So, its EPS will be $50. EPS is issued every quarter, indicating the stakeholders can evaluate the financial performance periodically.

EPS alone cannot indicate on the financial well-being of a firm. For a clear picture, it is vital to look into the price to earnings ratio of company.

EPS from continuing operations

Juno Therapeutics, Inc. (NASDAQ:JUNO) EPS from continuing operations was $-2.7157 for the fiscal ended 2016-03-31. For the quarter ended 2016-03-31, this figure was $-2.7157.

EPS contribution from parent

Juno Therapeutics, Inc. (NASDAQ:JUNO) confirmed basic EPS of $-2.7157 for the year ended 2016-03-31 from its parent group. Conversely, for the quarter closed 2016-03-31 it was $-2.7157.

Basic net EPS

Juno Therapeutics, Inc. (NASDAQ:JUNO) basic net EPS was $-0.72 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it came at $-0.72.

Consolidated diluted EPS

Juno Therapeutics, Inc. (NASDAQ:JUNO) consolidated diluted EPS was -2.7157 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it stood at $-2.7157.

Basic diluted EPS

Juno Therapeutics, Inc. (NASDAQ:JUNO) basic diluted EPS was $-0.7164 for the quarter ended 2016-03-31. For the year ended 2016-03-31, basic diluted EPS was $-0.7164.

Net diluted EPS

Juno Therapeutics, Inc. (NASDAQ:JUNO) posted net diluted EPS of $-2.72 for the fiscal closed 2016-03-31. For the quarter ended 2016-03-31, net diluted EPS was $-2.72.

Diluted EPS from parent

Juno Therapeutics, Inc. (NASDAQ:JUNO) diluted EPS from parent group was $-2.7157 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it stood at $-2.7157.

Juno Therapeutics, Inc. (NASDAQ:JUNO) net basic EPS was $-36.82 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it was $-36.82.

For the year ended 2016-03-31, basic shares outstanding were 8.443 while for the quarter ended 2016-03-31 is 8.443.

For the fiscal ended 2016-03-31, the diluted outstanding shares were 8.443 and for the quarter ended 2016-03-31 it was 8.443.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 1 times, 1 visits today)